BUSINESS WIRE: Yale-Boehringer Ingelheim Biomedical Data Science Fellowship Program Seeks to Attract Top Researchers from Around the World
10.05.2021 - 14:00 | Quelle: Business Wire | Lesedauer etwa 5 min. | Text vorlesen Stop Pause Fortsetzen facebook twitter
NEW HAVEN, Conn. & INGELHEIM, Germany (BUSINESS WIRE) 10.05.2021
Yale University, in partnership with Boehringer Ingelheim, today announced the launch of a Biomedical Data Science Fellowship program designed to attract and support some of the brightest and most innovative minds in data science from around the world.
Post-doctoral researchers awarded a three-year fellowship will have access to Yale’s robust computational resources, biomedical data repositories and faculty expertise. In addition, they will benefit from access to Boehringer Ingelheim’s corporate labs, scientists and executives. Applicants are invited to submit research proposals
VAntage Point
VA genetics program aims to increase mental health treatments for Veterans
VA’s Million Veteran Program, one of the world’s largest databases of health and genetic information, has published influential papers on genetic risk for a number of mental health conditions, including PTSD, anxiety, and substance use disorders. Some mental illnesses, such as opioid use disorder, schizophrenia, and bipolar disorder, have not been as well-represented among MVP volunteers.
Leaders of the Million Veteran Program (MVP) are addressing this gap through a new initiative called MVP MIND. It will survey 50,000 new participants with serious mental health conditions about their experiences. MVP officials believe such efforts will lead to more powerful research into these issues and better treatments.
Based on their analyses, the researchers are calling for prioritizing clinical trials of drugs targeting the proteins IFNAR2 and ACE2. The goal is to identify existing drugs, either FDA-approved or in clinical development for other conditions, that can be repurposed for the early management of COVID-19. Doing so, they say, will help keep people with the virus from being hospitalized.
IFNAR2 is the target for approved drugs often used by patients with relapsing forms of the central nervous system disorder multiple sclerosis. The researchers believe the most promising ACE2 therapy against COVID-19 is a drug that was developed before the pandemic began and has been evaluated in clinical trials to reduce inflammatory response in patients with severe respiratory disorders.
E-Mail
IMAGE: Dr. Juan P. Casas, a physician epidemiologist, led the study, which called for prioritizing clinical trials of drugs targeting two proteins. view more
Credit: Frank Curran
A new study using human genetics suggests researchers should prioritize clinical trials of drugs that target two proteins to manage COVID-19 in its early stages.
The findings appeared online in the journal
Nature Medicine in March 2021.
Based on their analyses, the researchers are calling for prioritizing clinical trials of drugs targeting the proteins IFNAR2 and ACE2. The goal is to identify existing drugs, either FDA-approved or in clinical development for other conditions, that can be repurposed for the early management of COVID-19. Doing so, they say, will help keep people with the virus from being hospitalized.